ArticleRespiratory research2023
Pseudomonas aeruginosa isolation is an important predictor for recurrent hemoptysis after bronchial artery embolization in patients with idiopathic bronchiectasis: a multicenter cohort study.
Article in Respiratory research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- New insights on Bronchial Artery Embolization (BAE) for hemoptysis: a systematic review.BMC pulmonary medicine · 2025Pooled it
- Pulmonary artery involvement contributes to the recurrence of hemoptysis after bronchial artery embolization in patients with chronic pulmonary aspergillosis.Journal of thoracic disease · 2026Article
- The hemodynamic and clinical characteristics of recurrent hemoptysis in bronchiectasis patients after vascular intervention procedures.Journal of thoracic disease · 2026Article
- Integrated traditional Chinese medicine and Western medicine strategies for the treatment of bronchiectasis: a comprehensive review.Chinese medicine · 2026Review
- Distinct bacterial profiles according to structural lung disease in patients undergoing bronchial artery embolization for hemoptysis.Frontiers in medicine · 2026Article
- Hemoptysis risk in hospitalized patients with bronchiectasis: development and external validation of a clinical prediction model.Frontiers in medicine · 2026Article
- Risk factors and prediction model for chronic bacterial infection in stable bronchiectasis in Shanghai, China.Frontiers in medicine · 2026Article
- The correlation between systemic inflammatory index and rebleeding after bronchial artery embolization: a retrospective cohort study.International journal of emergency medicine · 2025Article
- The Role of Early Rehabilitation in Treatment of Acute Pulmonary Embolism-A Narrative Review.Journal of clinical medicine · 2025Review
- OvercomingAntibiotics (Basel, Switzerland) · 2025Review
- Relation between vitamin D deficiency and Pseudomonas aeruginosa colonization in patients with bronchiectasis.BMC pulmonary medicine · 2025Article
- Observational
- Development and Validation of a Nomogram for Predicting Multidrug-ResistantInfection and drug resistance · 2025Article
- Development and validation of a novel nomogram for recurrent hemoptysis after bronchial artery embolization: a population-based cohort study.Frontiers in medicine · 2025Article
- The efficacy, safety, and related factors of bronchial artery embolization for hemoptysis: a systematic review and meta-analysis with subgroup analysis.Cardiovascular diagnosis and therapy · 2024Article
- Multi-drug resistant Pseudomonas aeruginosa isolation is an independent risk factor for recurrent hemoptysis after bronchial artery embolization in patients with idiopathic bronchiectasis: a retrospective cohort study.Respiratory research · 2024Article
- Epidemiology of bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 9 institutions in 1 country.
Funding
Abstract
backgroundNearly half of bronchiectasis patients receiving bronchial artery embolization (BAE) still have recurrent hemoptysis, which may be life-threatening. Worse still, the underlying risk factors of recurrence remain unknown.
methodsA retrospective cohort was conducted of patients with idiopathic bronchiectasis who received BAE from 2015 to 2019 at eight centers. Patients were followed up for at least 24 months post BAE. Based on the outcomes of recurrent hemoptysis and recurrent severe hemoptysis, a Cox regression model was used to identify risk factors for recurrence.
resultsA total of 588 individuals were included. The median follow-up period was 34.0 months (interquartile range: 24.3-53.3 months). The 1-month, 1-year, 2-year, and 5-year cumulative recurrent hemoptysis-free rates were 87.2%, 67.5%, 57.6%, and 49.4%, respectively. The following factors were relative to recurrent hemoptysis: 24-h sputum volume (hazard ratio [HR] = 1.99 [95% confidence interval [95% CI]: 1.25-3.15, p = 0.015]), isolation of Pseudomonas aeruginosa (HR = 1.50 [95% CI: 1.13-2.00, p = 0.003]), extensive bronchiectasis (HR = 2.00 [95% CI: 1.29-3.09, p = 0.002]), and aberrant bronchial arteries (AbBAs) (HR = 1.45 [95% CI: 1.09-1.93, p = 0.014]). The area under the receiver operating characteristic curve of the nomogram was 0.728 [95% CI: 0.688-0.769].
conclusionsIsolation of Pseudomonas aeruginosa is an important independent predictor of recurrent hemoptysis. The clearance of Pseudomonas aeruginosa might effectively reduce the hemoptysis recurrence rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.